to ШУУД ҮЗЭХ self-destruct rather
than multiply. The method was found to be effective when tackling dormant brain cancer cells that existing treatments are ineffective at eradicating.
While conventional treatments such as surgery, chemotherapy and radiation therapy are effective at removing active cancer cells, they often fail to eradicate a population of dormant, non-dividing cells that can later activate and regenerate tumors.
Unlike conventional treatments, UCD38B is effective at combating both
dormant cells and the dividing cells destroyed by other treatments. The
molecule works by targeting the urokinase plasminogen activator system –
a cellular regulatory system that's central to the healing process,
essentially telling cells whether to proliferate or destroy themselves.
The system has been found to be highly active in many aggressive cancers
including gliomas, and is thought to play a role in cancerous cell
growth and metastasizing.
UCD38B disrupts the intercellular part of the system, sending signalling
components to the mitochondria near the cancer cell nucleus rather than
the cell surface. In doing so, the destruction of the target cell is
triggered, whereas before it would have been told to proliferate.
The molecule was tested on laboratory rodents with implanted human
glioma cells. The results showed the UCD38B molecule to be effective
against the dormant cancer cells, without causing any adverse effects.
"We are hopeful that this new class of drug will one day become an
important adjunct to conventional therapies in fighting these especially
difficult-to-treat cancers," says Fredric Gorin, study lead and chair
of the UC Davis Department of Neurology School of Medicine.
Looking forward, the team will conduct a study using the drug in dogs
with high-grade glial brain cancers, for which there are are currently
no treatments.
No comments: